Viewing Study NCT00251394


Ignite Creation Date: 2025-12-25 @ 2:00 AM
Ignite Modification Date: 2025-12-26 @ 12:23 AM
Study NCT ID: NCT00251394
Status: COMPLETED
Last Update Posted: 2010-01-29
First Post: 2005-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module